SCHEMBL23943286

CC[C@H]1CC(C(=O)NCCNC(=O)CCC(=O)NCCNC(=O)[C@@H]2C[C@H](CC)[C@@H](O[C@@H]3O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]3O)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O[C@@H](CC4CCCCC4)C(=O)O)[C@H]3NC(C)=O)C2)C[C@@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O[C@@H](CC3CCCCC3)C(=O)O)[C@H]2NC(C)=O)[C@@H]1O[C@@H]1O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]1O

nearest known ligand 0.90

Predicted protein targets (top 2)

	gene	UniProt	supporting neighbours	confidence
▸	SELE	P16581	19/20	0.90

▸	MDK	P21741	1/20	0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL24489405	0.99	SELE (0.92)	SELEMDK
SCHEMBL24489363	0.97	SELE (0.85)	SELEMDK
SCHEMBL23943370	0.96	SELE (0.84)	SELE
SCHEMBL24489407	0.96	SELE (0.92)	SELEMDK
SCHEMBL25562384	0.96	SELE (0.84)	SELE
SCHEMBL22006658	0.96	SELE (0.84)	SELE
SCHEMBL26260592	0.95	SELE (0.82)	SELE
SCHEMBL25562417	0.95	SELE (0.82)	SELEMDK
SCHEMBL26408558	0.95	SELE (0.81)	SELE
SCHEMBL25447201	0.95	SELE (0.81)	SELEMDK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20230365609-A1	HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS	GLYCOMIMETICS, INC. (US)	2023-11-16	—	—	US	disclosed
US-11780873-B2	Highly potent multimeric e-selectin antagonists	GLYCOMIMETICS, INC. (US)	2023-10-10	—	—	US	disclosed
US-20210323990-A1	HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS	GLYCOMIMETICS, INC. (US)	2021-10-21	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20210323990-A1	HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS	SELE, SELP, SELPLG	SELE 1/4885MDK 2729/4885
US-11780873-B2	Highly potent multimeric e-selectin antagonists	SELE, SELP, SELPLG	SELE 1/4885MDK 2480/4885
US-20230365609-A1	HIGHLY POTENT MULTIMERIC E-SELECTIN ANTAGONISTS	SELE, SELP, SELPLG	SELE 1/4885MDK 2729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.